男性/女性性機能障害治療薬の世界市場2016-2026...市場調査レポートについてご紹介

【英文タイトル】Male and Female Sexual Dysfunctions: Drug Market Report and Forecasts 2016-2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Overview of the World Market for Sexual Dysfunctions Treatment
1.2 Why You Should Read This Report
1.3 How This Study Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Sexual Dysfunctions and Treatment Options
2.1 Diagnosis – ICD-10 and DSM-V
2.2 Male Sexual Dysfunctions
2.2.1 Sexual Desire Dysfunctions
2.2.2 Erectile Dysfunction
2.2.3 Priapism
2.2.4 Peyronie’s Disease
2.2.5 Premature Ejaculation
2.2.6 Hypogonadism
2.3 Female Sexual Dysfunctions
2.3.1 Dysfunctions of Arousal
2.3.2 Persistent Sexual Arousal Syndrome
2.3.3 Dysfunctions of Orgasm
2.3.4 Sexual Pain Dysfunctions
2.3.4.1 Dyspareunia
2.3.4.2 Vaginismus
2.3.5 Vulvodynia

3. The World Sexual Dysfunctions Drugs Market, 2015-2026
3.1 Global Sexual Dysfunctions Drugs Forecast 2015-2026
3.2 Sexual Dysfunction Drugs Market by Drug Class
3.2.1 PDE5 Inhibitors – Still Hold the Biggest Market Share
3.2.2 Prostaglandins – Dominated by Alprostadils
3.2.3 Androgens – Will New Delivery Technology Drive This Submarket?
3.2.4 Gonadotrophins – New Products Launched Expected
3.2.5 Other Drug Classes Market – Will See Significant Growth
3.3 Sexual Dysfunctions Drugs Market by Gender
3.3.1 Male Sexual Dysfunctions Drugs Market 2015-2026 – Declining as Originator Drugs Lose Patent Protection
3.3.2 Female Sexual Dysfunctions Drugs Market 2015-2026 – a Developing Market Holding Promising Commercial Potential

4. Sexual Dysfunction-Treating Drugs: Revenue Forecasts, 2015-2026
4.1 Cialis (Eli Lilly) – Faces Patent Expiry
4.2 Viagra (Pfizer) – Will Extended Patent in the US Protect Revenue?
4.3 Gonal-F (Merck KGaA) – Slow Growth in the First Half of the Forecast Period
4.4 Puregon (Merck & Co.) – Expected to Decline Significantly
4.5 Decapeptyl SR (Ipsen Ltd) – Growing Until the End of the First Half of the Forecast Period
4.6 Caverject Dual Chamber (Pfizer) – Growing During the First Half of the Forecast Period
4.7 Levitra (Bayer) – Sales Eroded by Cheaper PDE5 Inhibitors?
4.8 Nebido (Bayer) – Intramuscular Formulation of Testosterone Undecanoate
4.9 Testim (Ferring Pharmaceuticals) – Differentiated by Consistent Transdermal Absorption
4.10 Priligy (J&J/A. Menarini Pharma UK SRL) – SSRI to Treat Premature Ejaculation
4.11 Stendra/Spedra (VIVUS/Endo/Auxilium Pharmaceuticals) – Newest PDE5 Inhibitor
4.12 MUSE (Meda Pharmaceuticals) – Suppository Prostaglandin
4.13 Viridal Duo/Edex (UCB Pharma/Auxilium Pharmaceuticals) – Growing Strongly in the First Half of the Forecast Period
4.14 Tostran (ProStrakan Pharmaceuticals) – Eroded by Generic Competition Since 2014
4.15 Vitaros (Takeda) – Topical Formulation of Alprostadil
4.16 Restandol Testocaps (Merck & Co.) – Testosterone Replacement
4.17 Sustanon 250 (Aspen Pharma Trading) – Preferred Testosterone Replacement in the UK
4.18 Bemfola (Finox Biotech UK & Ireland Ltd.) – Biosimilar
4.19 Menopur (Ferring Pharmaceuticals) – a Preparation of Gonadotrophins
4.20 Pregnyl (Merck & Co.) – to Treat Hypogonadism
4.21 Androcur (Bayer Plc) – to Treat Androgen-related Conditions
4.22 Gonapeptyl (Ferring Pharmaceuticals) – Depot Injection
4.23 Intrinsa (Procter & Gamble) – Testosterone Patch

5. Emerging Therapies for Sexual Disorders
5.1 Vitaros (Takeda) – Topical Cream to Treat Erectile Dysfunction
5.2 Addyi (Sprout/Valeant Pharmaceuticals) – First Approved Drug for Female Sexual Dysfunction
5.3 Xiapex (Auxilium Pharmaceuticals)- First Approved Drug for Peyronie’s Disease

6. Leading Companies in the Sexual Dysfunction Drugs Market
6.1 Eli Lilly – Leading With Cialis
6.2 Pfizer – Will It Overtake Eli Lilly in This Forecast Period?
6.3 Merck KGaA – Driven by Sales in Emerging Markets
6.4 Merck & Co. – Will It Soon Lose Its Share to Competitors?
6.5 Ipsen Ltd – Ongoing Clinical Trials for Decapeptyl May Drive Further Growth
6.6 Bayer – Orodispersible Form of Levitra Not Pushing Revenue?

7. Leading National Markets: Revenue Forecasts, 2015-2026
7.1. The US Sexual Dysfunctions Drugs Market, 2015-2026 – Leader of the Pack
7.2. The Japanese Sexual Dysfunctions Drugs Market, 2015-2026 – Still Driven by Viagra and Cialis Sales
7.3 EU5 Sexual Dysfunctions Drugs Market, 2015-2026 – Cost Containment Will Slow the Market
7.4 BRIC Sexual Dysfunctions Drugs Market, 2015-2026 – Driven by Growth in China and India
7.5 Other Regions’ Sexual Dysfunctions Drugs Market, 2015-2026 – Expected High Growth Rate

8. R&D Pipelines for Sexual Dysfunctions Treatment
8.1 R&D Pipeline Drugs for Male Sexual Dysfunctions – Still Dominated by ED
8.1.1 Tissue Genesis Cell Isolation System (Tissue Genesis, Inc.) – ED
8.1.2 Adipose-Derived Stem Cell Injection (Ageless Regenerative Institute) – ED
8.1.3 Selegiline (University of South Florida) – ED
8.1.4 VL#FIA3-30 (VasoLead) – ED
8.1.5 MED2002 (Futura Medical) – ED
8.1.6 MED2005 (Futura Medical Developments Ltd) – ED
8.1.7 Fispemifene (NexMed) – ED and Secondary Hypogonadism
8.1.8 Transdermal Androgel (Johns Hopkins University) – Priapism
8.1.9 Adipose Tissue Stem Cell Injection (Man Clinic for Andrology, Male Infertility and Sexual Dysfunction) – Peyronie’s Disease
8.1.10 AA4500 and ErecAid Esteem Manual Vacuum Therapy System (Endo Pharmaceuticals) – Peyronie’s Disease
8.1.11 H-22411(Allergan) – Peyronie’s Disease
8.1.12 AA4500 (Allergan) – Peyronie’s Disease
8.1.13 IX-01 (Ixchelsis Limited) – Premature Ejaculation
8.1.14 CDFR0812-15 (CTC Bio, Inc.) – Premature Ejaculation
8.2 R&D Pipeline Drugs for Female Sexual Dysfunctions – Emerging Therapies
8.2.1 Tribulus Terrestris – Female Hypoactive Sexual Desire Disorder
8.2.2 Bremelanotide (Palatin Technologies) – Female Hypoactive Sexual Desire Disorder
8.2.3 Lybridos (Emotional Brain NY Inc.) – Female Hypoactive Sexual Desire Disorder
8.2.4 Lorexys (S1 Biopharma) – Female Hypoactive Sexual Desire Disorder
8.2.5 SST-6007 (Strategic Science & Technologies, LLC) – Female Hypoactive Sexual Desire Disorder
8.2.6 TBS-2 (Acerus Pharmaceuticals Corporation) – Orgasmic Disorder
8.2.7 SST-6006 (Strategic Science & Technologies, LLC) – Female Sexual Dysfunction
8.2.8 Fluocinonide Cream (OHSU Knight Cancer Institute National Cancer Institute (NCI)) – Painful Sexual Intercourse

9. Qualitative Analysis of the Sexual Dysfunctions Drugs Market 2015-2026
9.1 SWOT Analysis of the Sexual Dysfunctions Drugs Market, 2015-2026
9.1.1 Strengths
9.1.2 Weaknesses
9.1.3 Opportunities
9.1.4 Threats
9.2 STEP Analysis of the Sexual Dysfunctions Drugs Market, 2015-2026
9.2.1 Social
9.2.2 Technological
9.2.3 Economic
9.2.4 Political

10. Research Interviews from Our Survey – 2015
10.1 Dr. Carl Spana and Mr. Stephen Wills, Palatin Technologies
10.1.1 Palatin Technologies, Inc.
10.1.2 Female Sexual Dysfunction Market – What Are the Challenges?
10.1.3 Industry Effort to Bridge the Gaps
10.1.4 Drivers and Restraints of the FSD Market
10.1.5 Bremelanotide – On-Demand Treatment for HSDD
10.1.6 Designing Clinical Trials to Assess Drugs for FSDs – Remains a Challenge?
10.1.7 Commercial Potential of Bremelanotide
10.2 James Barder, CEO, Futura Medical
10.2.1 Futura Medical
10.2.2 Will the ED Treatment Market Show Growth?
10.2.3 Unmet Needs of ED Treatment and Management
10.2.4 MED2002 for ED – Targeted Delivery
10.2.5 DermaSys – Improves Permeation of APIs through the Skin
10.2.6 DermaSys –Therapeutic Benefits to Other Therapeutic Areas?
10.2.7 MED2002 – Could Potentially Meet the Unmet Demand in ED

11. Conclusions
11.1 Male Sexual Dysfunction Drugs Market
11.2 Female Sexual Dysfunction Drugs Market
11.3 Leading National Markets
11.4 Drugs in the Pipeline


【レポート販売概要】

■ タイトル:男性/女性性機能障害治療薬の世界市場2016-2026
■ 英文:Male and Female Sexual Dysfunctions: Drug Market Report and Forecasts 2016-2026
■ 発行日:2015年12月
■ 調査会社:visiongain
■ 商品コード:VGAIN5122114
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。